News

Overall, the results mirrored previous reports demonstrating that patients on ocrelizumab before or during pregnancy did not have elevated risk of adverse pregnancy and infant outcomes.

The associate professor of neurology at Harvard Medical School talked about results from a recent study that evaluated the efficacy of inebilizumab versus rituximab in treating NMOSD.

Following the mixed results, NS Pharma is working with the FDA to determine how to proceed with viltolarsen.

Scott Newsome, DO, director of the Stiff Person Syndrome Center and professor of neurology at Johns Hopkins Medicine, provided clarity on the 1-year data of the OCARINA II study assessing subcutaneous ocrelizumab.

The FDA granted fast track designation to TPN-101, an investigational therapy for progressive supranuclear palsy, based on promising phase 2a study results.

The director of research in the Jane and John Justin Neurosciences Center at Cook Children's Health Care System talked about ongoing research on biomarkers to enhance treatment and improve cognitive outcomes. [WATCH TIME: 6 minutes]

As part of our monthly clinician spotlight, NeurologyLive® highlighted neuromuscular disorder expert Merit Cudkowicz, MD, MSc, chair of neurology at Massachusetts General Hospital.

Overall, a significantly greater amount of patients on Andexanet had hematoma volume expansion of 35% or less; however, these patients had greater risk of thrombolytic events and lower modified Rankin scale scores at 30 days.

Here's some of what is coming soon to NeurologyLive® this week.

The 38th CMSC Annual Meeting is set to be held May 29-June 1, 2024, in Nashville, Tennessee. The International Journal of MS Care has published the abstracts.

The International Journal of MS Care publishes the abstracts for the CMSC Annual Meeting, which is set to be held May 29-June 1, 2024, in Nashville, Tennessee.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is on Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD).

DC Medicaid covers over 300,000 members in the greater Washington D.C. area, allowing increased access to the FDA-cleared product.

Ataluren, which was conditionally approved in Europe in 2014, had its real-world use backed by data from the STRIDE registry.

Neurology News Network. for the week ending May 25, 2024. [WATCH TIME: 4 minutes]

The lead neuroscientist and lead data scientist at Rune Labs talked about leveraging mobility data to monitor progression in patients with Parkinson disease. [WATCH TIME: 7 minutes]

Khashayar Dashtipour, MD, PhD, an associate professor of neurology at the Loma Linda University Health System, provided an overview of an upcoming CME-credited educational course on movement disorders scheduled for June 1st in Minnetonka, Minnesota.

The professor and chair of rehabilitation medicine at UT Health San Antonio talked about the newly published guidelines for the assessment and management of spasticity in patients with neurological conditions. [WATCH TIME: 5 minutes]

The double-blind, placebo-controlled trial, which includes 2 dosing regimens of COYA 302, is expected to have topline data reported later this summer.

A trio of clinicians from Cleveland Clinic provided perspectives on the advances in neurology seen at the 2024 AAN Annual Meeting, specifically focusing in on epilepsy, stroke, and multiple sclerosis.

Adrienne Viscio, a 63-year-old patient diagnosed with primary progressive aphasia from CaringKind, talked about how she finds solace, engagement, and cognitive benefits through gardening.

Dyne aims to pursue expedited approval pathways for DYNE-251, leveraging dystrophin as a surrogate biomarker.

The vascular neurosurgeon and professor of neurological surgery at The Ohio State University Wexner Medical Center spoke about advancements in stroke treatment, including endovascular thrombectomy and new drug therapies, that aim to address unmet need in patients. [WATCH TIME: 5 minutes]

DYNE-101 demonstrated dose-dependent splicing correction, with the 5.4 mg/kg cohort showing a 27% mean correction at 3 months.

The phase 3 REACH trial investigating Fulcrum Therapeutics’ losmapimod in patients with facioscapulohumeral muscular dystrophy remains on track with topline data anticipated in the fourth quarter of 2024.

The study showed durable improvements in VEP latency with bexarotene, suggesting long-term benefits from exposure to a remyelinating drug.

Of respondents who qualified for preventive treatment who were not currently using preventive medication, the majority (86.1%) had also never previously used preventive medication.

Stephanie Richardson, MS, CCC-SLP, an outpatient lead speech-language pathologist at Brooks Rehabilitation, discussed the unique aspects of speech therapy and the pivotal role it plays in helping patients with swallowing and other related functions.

The neurologist and neuro-oncologist at the Preston Robert Tisch Brain Tumor Center at Duke University provided clarity on a new analysis of the INDIGO study highlighting treatment benefits of vorasidenib in patients with IDH mutant grade 2 gliomas.

Larimar Therapeutics anticipates interim data from the open label extension study assessing nomlabofusp in patients with Friedreich Ataxia in the fourth quarter of 2024.